The CMS should end direct and indirect remuneration fees, since beneficiaries often don't see cost benefits and DIR fees can lead to negative reimbursement for pharmacies, wrote more than 50 members of Congress in a letter to HHS and the CMS. "We also urge CMS to ensure patient access to specialty pharmacies is not limited by the use of inapplicable Star Rating measures," they wrote.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.